This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
這位biontech分析師轉爲看好；以下是週二的前5名升級
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
華爾街頂級分析師改變了對這些頂級公司的展望。如需查看包括升級和降級在內的所有分析師評級變化的完整視圖，請參閱我們的分析師評級頁面。
- BTIG analyst Julian Harrison upgraded the rating for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) from Neutral to Buy and announced a price target of $8. Aclaris Therapeutics shares closed at $3.14 on Monday. See how other analysts view this stock.
- HSBC analyst Wesley Brooks upgraded the rating for QuantumScape Corporation (NYSE:QS) from Reduce to Hold and announced a price target of $5.3. QuantumScape shares closed at $4.73 on Monday. See how other analysts view this stock.
- Evercore ISI Group analyst Cory Kasimov upgraded the rating for BioNTech SE (NASDAQ:BNTX) from In-Line to Outperform and boosted the price target from $110 to $125. BioNTech shares closed at $101.87 on Monday. See how other analysts view this stock.
- Canaccord Genuity analyst Matthew Lee upgraded Bank of Nova Scotia (TSX:BNS) from Hold to Buy and raised the price target from C$71 to C$84. See how other analysts view this stock.
- Jefferies analyst Roger Song upgraded the rating for Aclaris Therapeutics, Inc. (NASDAQ:ACRS) from Hold to Buy and raised the price target from $2 to $7. Aclaris Therapeutics shares closed at $3.14 on Monday. See how other analysts view this stock.
- BTIG分析師朱利安·哈里森將Aclaris Therapeutics, Inc.（納斯達克：ACRS）的評級從中立上調至買入，並宣佈目標價爲8美元。Aclaris Therapeutics的股票週一收盤價爲3.14美元。看看其他分析師對該股票的看法。
- 匯豐銀行分析師韋斯利·布魯克斯將QuantumScape Corporation（紐交所：QS）的評級從減持上調至持有，並宣佈目標價爲5.3美元。QuantumScape的股票週一收盤價爲4.73美元。看看其他分析師對該股票的看法。
- Evercore ISI Group分析師科裏·卡西莫夫將BioNTech SE（納斯達克：BNTX）的評級從市場持平上調至跑贏大盤，並將目標價從110美元提高至125美元。BioNTech的股票週一收盤價爲101.87美元。看看其他分析師對該股票的看法。
- Canaccord Genuity分析師馬修·李將豐業銀行（tsx：BNS）的評級從持有上調至買入，並將目標價從71加元提高至84加元。看看其他分析師對該股票的看法。
- 傑弗裏分析師羅傑·宋將Aclaris Therapeutics, Inc.（納斯達克：ACRS）的評級從持有上調至買入，並將目標價從2美元提高至7美元。Aclaris Therapeutics的股票週一收盤價爲3.14美元。看看其他分析師對該股票的看法。
Considering buying BNTX stock? Here's what analysts think:
考慮購買BNTX股票嗎？以下是分析師的看法：
Read This Next:
Read This Next:
- Jim Cramer: Super Group Finally 'Broke Out,' This Basic Materials Stock Is 'Very Hard To Own Here'
- 吉姆·克萊默：Super Group終於『衝破』，這家基礎材料股票『在這裏非常難以擁有』
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間